PMID: 8581373Oct 1, 1995Paper

Expression of monovalent and bivalent antibody fragments in Escherichia coli

Journal of Hematotherapy
S D GrantW J Harris

Abstract

The technology of humanization of rodent antibodies has opened the way for a broad range of therapeutic antibodies with very low immunogenicity, which are, therefore, suitable for repeated dosing. Such intact antibodies have extended serum half-lives and biodistribution profiles very similar to human antibodies. For some applications, however, the ideal therapeutic should have reduced serum half-life and altered biodistribution patterns typical of antibody fragments, such as Fab or single chain Fv. Bispecific antibody fragments offer exciting additional therapeutic possibilities, but their successful manufacture and purification on a large scale require the development of new methods. Antibody fragments often assemble in Escherichia coli as monovalent fragments with reduced affinities. We describe the spontaneous assembly of bivalent antibody fragments in E. coli and methods of purification that yield either bivalent or monovalent molecules as required.

References

Apr 1, 1991·Trends in Biotechnology·R E Bird, B W Walker
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·V K ChaudharyI Pastan
Jul 1, 1995·Journal of Chemical Technology and Biotechnology·B M GrahamW J Harris
Apr 1, 1995·The Journal of Applied Bacteriology·P MolloyW J Harris
Feb 10, 1995·Journal of Molecular Biology·P PackA Plückthun
Feb 1, 1994·Molecular Immunology·D P McGregorW J Harris
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·P HolligerG Winter
Jan 1, 1993·International Reviews of Immunology·J S HustonH Oppermann

❮ Previous
Next ❯

Citations

Oct 30, 2001·Virus Research·P M CupitC Cunningham
Sep 28, 2005·Reproductive Biology and Endocrinology : RB&E·Tarja Sorsa-LesliePaul A Fowler
Nov 24, 1999·Journal of Agricultural and Food Chemistry·S D GrantW J Harris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.